Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $5.754B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.25pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | $23.83 | Day High | $24.63 | Day Low | $23.74 | |||
| Daily Volume | 1219489 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | $24.49 | 2000 | 0 | $24.60 | 1849 | |
Directors & Senior Management
| Mr. Alex Haro | Co-founder & Non-Executive Director |
| Ms. Brittany Morin | Independent Non-Executive Director |
| Mr. Charles J. Prober | Non-Executive Director |
| Mr. Christopher Hulls | Co-Founder & Executive Chairman |
| Mr. David Wiadrowski | Independent Non-Executive Director |
| Ms. Heather Houston | Chief People Officer |
| Mr. James S. Synge | Independent Non-Executive Director |
| Mr. James Selby | Chief Revenue Officer |
| Mr. John Philip Coghlan | Independent Director |
| Jolanta Masojada | Head of Investor Relations |
| Mr. Justin Moore | Chief Technology Officer |
| Ms. Lauren Antonoff | CEO & Director |
| Mr. Mark Goines | Lead Independent Director |
| Mr. Matthew Cullen | General Counsel & Corporate Secretary |
| Ms. Melissa Goodell | Executive Assistant |
| Mr. Mike Zeman | Chief Marketing Officer |
| Ms. Randi Zuckerberg | Independent Non-Executive Director |
| Mr. Raymond T. Jones | Vice President of Investor Relations |
| Mr. Russell Burke | Chief Financial Officer |
Data source: ADVFN
